A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer
- 1Department of Medicine, University of North Carolina, Chapel Hill 27599-7555, USA. rsandler@med.unc.edu
- 0Department of Medicine, University of North Carolina, Chapel Hill 27599-7555, USA. rsandler@med.unc.edu
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Regular aspirin use significantly reduced colorectal adenoma incidence in patients with prior colorectal cancer. This study found fewer adenomas and a longer time to adenoma detection with daily aspirin.
Area Of Science
- Oncology
- Gastroenterology
- Pharmacology
Background
- Preclinical and human studies suggest aspirin may lower colorectal adenoma risk.
- Colorectal adenomas are precursors to most colorectal cancers.
Purpose Of The Study
- To evaluate the effect of daily aspirin on colorectal adenoma incidence.
- To assess aspirin's impact on adenoma recurrence and development time in cancer survivors.
Main Methods
- A randomized, double-blind trial involving 635 patients with prior colorectal cancer.
- Participants received either 325 mg aspirin daily or a placebo.
- Outcomes included adenoma proportion, number, and time to development, with adjusted relative risks.
Main Results
- 17% of aspirin users and 27% of placebo users developed adenomas (P=0.004).
- Aspirin significantly reduced the mean number of adenomas and the risk of recurrent adenomas (RR=0.65).
- Aspirin use was associated with a longer time to first adenoma detection (HR=0.64, P=0.022).
Conclusions
- Daily aspirin use significantly decreases colorectal adenoma incidence.
- Aspirin demonstrates a protective effect against adenoma development in patients with a history of colorectal cancer.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.